Comparative Pharmacology
Head-to-head clinical analysis: SPECTROBID versus TOTACILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPECTROBID versus TOTACILLIN.
SPECTROBID vs TOTACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Spectrobird (bacampicillin) is a prodrug of ampicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Bactericidal: inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation. Active against gram-positive bacteria and some gram-negative bacteria.
400 mg orally twice daily or 200 mg orally four times daily for 10-14 days. For acute exacerbations of chronic bronchitis: 400 mg orally twice daily for 10 days.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged to 6-10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 1.0-1.5 hours in normal renal function. Extended to 2-6 hours in renal impairment; requires dose adjustment when CrCl <30 mL/min.
Renal: ~75-85% unchanged drug; fecal/biliary: ~15-25% as metabolites and unchanged drug.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5% as unchanged drug and metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic